| 000 | 01709 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515214139.0 | ||
| 264 | 0 | _c20100624 | |
| 008 | 201006s 0 0 eng d | ||
| 022 | _a1938-2723 | ||
| 024 | 7 |
_a10.1177/1076029609350621 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDiaz, Josephina | |
| 245 | 0 | 0 |
_aProfiling of heparin-induced thrombocytopenia antibody levels in patients with and without diabetes. _h[electronic resource] |
| 260 |
_bClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis _cApr 2010 |
||
| 300 |
_a121-5 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAutoantibodies _xblood |
| 650 | 0 | 4 | _aAutoimmunity |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xcomplications |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeparin _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPlatelet Factor 4 _ximmunology |
| 650 | 0 | 4 | _aPolypharmacy |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 |
_aThrombocytopenia _xchemically induced |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aPrechel, Margaret | |
| 700 | 1 | _aEmanuele, Maryann | |
| 700 | 1 | _aEmanuele, Nicholas | |
| 700 | 1 | _aWalenga, Jeanine M | |
| 773 | 0 |
_tClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis _gvol. 16 _gno. 2 _gp. 121-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/1076029609350621 _zAvailable from publisher's website |
| 999 |
_c19663822 _d19663822 |
||